Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 46.50 0.00 08:00:28
Bid Price Offer Price High Price Low Price Open Price
45.00 48.00 47.50 46.50 46.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -24.13 -18.90 50
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 46.50 GBX

Verona Pharma (VRP) Latest News

More Verona Pharma News
Verona Pharma Takeover Rumours

Verona Pharma (VRP) Discussions and Chat

Verona Pharma Forums and Chat

Date Time Title Posts
14/7/202010:24Verona Pharma: Developing first in class drugs for respiratory diseases1,286
30/10/201808:41Still time to look at Verona Pharma (VRP)-
01/8/201810:42Verona Pharma (VRP) One to Watch -
16/2/201517:30Verona Pharma with Charts & News11,549
24/11/201112:54verona pharma173

Add a New Thread

Verona Pharma (VRP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Verona Pharma trades in real-time

Verona Pharma (VRP) Top Chat Posts

DateSubject
16/7/2020
09:20
Verona Pharma Daily Update: Verona Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VRP. The last closing price for Verona Pharma was 46.50p.
Verona Pharma Plc has a 4 week average price of 46.50p and a 12 week average price of 37p.
The 1 year high share price is 99.50p while the 1 year low share price is currently 27.50p.
There are currently 106,536,006 shares in issue and the average daily traded volume is 27,633 shares. The market capitalisation of Verona Pharma Plc is £49,539,242.79.
20/2/2020
15:21
bioking: DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYY Diurnal (DNL) Market Cap £27 M Price: 31p Upcoming Catalysts: MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 2Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses
13/1/2020
08:23
ih_116147: Next MONSTER opp is DNL ... The most underpriced and attractive british biotech company with MASSIVE upside potential .Still think this sleeping giant has 10+ bagger upside potential and 2020 could be the year for DNL with all the approvals and partnerships expected during the year .GL Diurnal Group(DNL) Market Cap £24 M Price: 29p DCF valuation of 202p per share https://www.hardmanandco.com/wp-content/uploads/2019/11/DNL-2019-results-5-November-2019.pdf Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses Presentation hxxps://www.diurnal.co.uk/media/36783/full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf Upcoming Catalysts: US-NDA acceptance for Alkindi in Februry 2020 MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 1Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 $88m market opportunity (Europe and US) for Paediatric AI (inc CAH) $351m market opportunity (Europe and US) for Congenital Adrenal Hyperplasia $2,767m market opportunity (Europe and US) for Adrenal Insufficiency Ceo bought another 25k shares at 30p hxxps://www.ii.co.uk/news/director-dealings-rnsLSE20191216114654_14350421
06/1/2020
22:10
diversification: Nice finish in US and after hours. New website up and running today and it would appear it's all about to come together. Share price is irrelevant given imminent Phase II results for a product with a massive target market. If successful current shareholders invested below 100p should be very happy.
30/7/2019
23:14
shakin not stirred: By the time we get the update someone might wish to ask what JAk thinks of the share price and if the drug is all he reckons as no sign of Significant shareholder value. If so then in which decade should we expect to see it. Why do they reward themselves disproportionately to the share price performance and is he aware no one is currently in profit yet he has continued to recruit at will and no further advancement to our lead drug if not only drug enisfenterine in my opinion. Does he see 40p as representing significant shareholder value. Please someone ask the question. Ask Jak at what share price level does this need to reach for them to call it a day and put shareholders out of their misery. All the above my opinion and can anyone post a Nasdaq share price and how that equates at the exchange rate to the share price on aim. Sorry for being slightly as have forgotten how many shares are worth the other as seems an age ago
15/7/2019
09:56
haff1: Ive been in VRP for nearly 10 years now!! Foolish I know but its always been jam tomorrow for 10 years with a stedily decreasing share price and value...Its so depressing its untrue. I really cant afford to come out now and have to just hope ....though I stopped holding my breadth about 6 years ago ..... no 8 years ago....that it will come to market and have been worthwhile! Trouble is will it come to market before I pass away?
09/1/2019
13:11
tomboyb: https://uk.advfn.com/stock-market/london/verona-pharma-VRP/share-news/Verona-Pharma-plc-Verona-Pharma-Receives-Who-Appro/79020332 I wonder if saffy is buying a few -
20/2/2018
19:43
combo83: The risk/reward here currently looks very favourable. Well funded, important newsflow within 1-2 months, consistent director buying, and different brokers with price targets at multiples of the current share price. GLA, could be a very interesting year. PS - timboo, perhaps time for an update of the header? :)
09/11/2017
12:04
haff1: Its a shame the share price doesnt reflect this..
23/6/2017
08:31
kwizza: Is this a new low for the share price
23/2/2017
11:22
shakin not stirred: I am waiting to see if Nasdaq listing makes a difference but need to get to £2 new money to break even. Will bale out when that is reached. Unless anything materially changes as to indicating a good news flow. At the moment it is a Jam tomorrow as have been the last few years for me and longer for others. None of us have invested in companys for F.A. but that is the current return at this moment in time. That is the current reality of the share price.
Verona Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
VRP
Verona Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200716 17:57:22